Business Wire

TDK Hosts Youth Initiative at IAAF World Relays Yokohama 2019

13.5.2019 13:59:00 EEST | Business Wire | Press release

Share

As part of the IAAF World Relays Yokohama 2019, held May 11–12 at Yokohama’s Nissan Stadium, official IAAF partner TDK (TOKYO:6762) presented the latest installment in its Rising Stars Clinic, a unique initiative in which aspiring young athletes are given the opportunity to train alongside some of the world’s leading track & field competitors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190513005396/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

TDK's Rising Stars Clinic gave young people a chance to interact with world-class athletes at Yokohama's Nissan Stadium (Photo: Business Wire)

The May 11 session saw three star athletes—Shingo Suetsugu (Japan), 4x100m silver medalist at the 2008 Summer Olympics in Beijing; Nethaneel Mitchell-Blake (Great Britain), 4x100m gold medalist at the 2017 IAAF World Championships in London; and Aleia Hobbs (United States), 4x100m gold medalist at this IAAF World Relays Yokohama —lead their young charges through special coaching sessions and an exclusive stadium tour.

As well as hands-on guidance for stretches, warm-up exercises, and baton relay practice, the 16 participants, selected from a local athletics club and international school, were treated to professional gear checks and a backstage tour for an in-depth taste of exactly what race day is like for athletes competing at the highest level. The finale was a 4x100m relay race on the main track, followed by mock media interviews in the stadium’s mixed zone. “It was so fun—a really great experience,” said one participant. “I was thrilled to run in the same stadium as these world-class athletes,” added another.

Rising Stars coach Suetsugu also expressed his enjoyment. “I was so happy to hear these young people say how much fun they were having,” he said. “I love kids, so it was a pleasure to work with this group. It was great how their determination to win came through in that final race. And besides winning and losing, I hope collective enjoyment of activities like today’s mock stadium entrances will help cement their love of running.”

Suetsugu added, “The Rising Stars Clinic gives the next generation a valuable chance to interact with world-class athletics competitors, so I hope it can continue for many years to come.”

About Rising Stars Clinic

The Rising Stars Clinic is a program unique to TDK that reflects TDK’s communications slogan “Attracting Tomorrow.” It gives young athletes an opportunity to interact with top-class athletes and see them compete at the highest level in the IAAF World Championships. The program aims to inspire young athletes to become the next generation of top athletes and is aimed at students who have an interest in track and field.

About TDK Corporation

TDK Corporation is a leading electronics company based in Tokyo, Japan. It was established in 1935 to commercialize ferrite, a key material in electronic and magnetic products. TDK's comprehensive portfolio features passive components such as ceramic, aluminum electrolytic and film capacitors, as well as magnetics, high-frequency, and piezo and protection devices. The product spectrum also includes sensors and sensor systems such as temperature and pressure, magnetic, and MEMS sensors. In addition, TDK provides power supplies and energy devices, magnetic heads and more. These products are marketed under the product brands TDK, EPCOS, InvenSense, Micronas, Tronics and TDK-Lambda. TDK focuses on demanding markets in the areas of information and communication technology and automotive, industrial and consumer electronics. The company has a network of design and manufacturing locations and sales offices in Asia, Europe, and in North and South America. In fiscal 2019, TDK posted total sales of USD 12.5 billion and employed about 105,000 people worldwide.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Aya Tohyama, TDK Corporation
+81-3-6778-1055

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 16:30:00 EEST | Press release

FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and execution management workflow is becoming increasingly important. FlexTrade's integration with Portx builds on FlexONE's existing real-time front-office risk analytics capabilities, inclu

Xsolla Connect Returns to Brighton13.7.2026 16:22:00 EEST | Press release

Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event will build on that momentum by providing attendees with a dedicated space to connect with peers

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ

Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release

Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli

HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release

HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye